News BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Real-time Estimate Cboe BZX Other stock markets 12:36:39 2024-05-06 pm EDT			5-day change	1st Jan Change
82.56 ^USD	+0.14%		+0.65%	-14.27%

May. 04	Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	CI
May. 04	BioMarin Pharmaceutical Inc. Announces That Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

New Data for BioMarin's VOXZOGO for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society Annual Meeting	10:43am	AQ
Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	May. 04	CI
BioMarin Pharmaceutical Inc. Announces That Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	May. 04	CI
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...	May. 03
BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says	Apr. 29	MT
Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $85 From $83, Maintains Sector Perform Rating	Apr. 25	MT
Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating	Apr. 25	MT
Transcript : BioMarin Pharmaceutical Inc., Q1 2024 Earnings Call, Apr 24, 2024	Apr. 24
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours	Apr. 24	MT
BioMarin: Q1 Earnings Snapshot	Apr. 24	AQ
(BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95	Apr. 24	MT
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M	Apr. 24	MT
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71	Apr. 24	MT
BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
BioMarin Reports Record Financial Results for the First Quarter 2024	Apr. 24	PR
Biomarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	Apr. 24	CI
BioMarin Pharmaceutical : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K	Apr. 23	PU
BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says	Apr. 22	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	Apr. 15	MT
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET	Apr. 10	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Summary

Filters